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Glycosaminoglycans	  and	  Heparin	  Analogs:	  
Glycosaminoglycans	  (GAGs)	  play	  a	  critical	  role	  in	  the	  pathophysiology	  of	  diseases	  
including	  diabetes,	  atherosclerosis,	  and	  metastasis.	  8,11 GAGs	  localize	  proteins	  and	  
enzymes	  at	  their	  site	  of	  action	  to	  facilitate	  their	  physiological	  functions	  and	  in	  some	  
cases	  prevent	  their	  proteolytic	  degradation.	  8	  They	  also	  regulate	  protein	  secretion	  and	  
gene	  expression	  in	  certain	  tissues	  by	  mechanisms	  involving	  events	  in	  the	  membrane	  and	  
nucleus.	  8,11	  	  
Heparin	  sulfate	  (HS),	  an	  analog	  of	  heparin,	  is	  classified	  as	  a	  glycosaminoglycan	  as	  
well.	  This	  molecule	  is	  present	  in	  the	  cell	  surface	  membranes	  and	  is	  essential	  to	  the	  
extracellular	  matrix.	  6	  HS	  has	  a	  structure	  similar	  to	  that	  of	  heparin	  consisting	  
predominantly	  of	  a	  repeating	  disaccharide	  comprised	  of	  β-­‐D-­‐glucuronic	  acid	  and	  N-­‐
acetyl-­‐α-­‐D-­‐glucosamine.	  7	  The	  D-­‐glucuronic	  acid	  moieties	  are	  not	  as	  fully	  sulfated	  
resulting	  in	  less	  of	  a	  negative	  charge	  than	  heparin.	  7,8	  According	  to	  a	  study	  done	  by	  F.	  
Zhang,	  Z.	  Zhang,	  X.	  Lin,	  et	  al.,	  the	  FGF-­‐Heparin	  complex	  is	  more	  stable	  than	  the	  FGF-­‐HS	  
complex	  since	  heparin	  decassacharide	  and	  the	  6-­‐desulfated	  heparin	  decassaccharide	  
more	  strongly	  inhibited	  binding	  of	  the	  FGF-­‐FGFR	  complex	  to	  heparin.	  7	  
Sucrose	  octasulfate	  (SOS)	  is	  another	  structural	  analog	  of	  heparin	  and	  has	  shown	  to	  
mimic	  heparin	  by	  supporting	  the	  FGF-­‐mediated	  cell	  proliferation	  activity.	  14,17	  Both	  
heparin	  and	  SOS	  are	  shown	  to	  promote	  ostocalcin	  expression	  and	  promote	  complete	  
closure	  of	  the	  cranial	  sutures.	  14,16	  SOS	  activates	  the	  FGF	  receptor	  by	  binding	  to	  the	  
heparin	  binding	  sites	  in	  both	  FGF	  and	  the	  D2	  domain	  of	  the	  FGFR.	  14,16	  Charge	  
interactions	  play	  a	  dominant	  role	  in	  the	  D2-­‐SOS	  interaction	  because	  the	  SOS	  binds	  to	  
positively	  charged	  residues	  in	  the	  D2	  domain.	  14	  Since	  the	  SOS-­‐D2	  domain	  interaction	  is	  
in	  the	  same	  range	  as	  that	  reported	  for	  heparin	  binding,	  the	  D2	  domain	  largely	  
contributes	  the	  heparin-­‐binding	  site.	  14	  The	  crystal	  structure	  of	  the	  FGF2-­‐FGFR1-­‐SOS	  
complex	  at	  2.6	  Angstrom	  resolution	  reveals	  a	  symmetric	  assemblage	  of	  two	  1:1:1:FGF2-­‐
FGFR1-­‐SOS	  ternary	  complexes.	  15	  SOS	  binds	  to	  FGF	  and	  FGFR	  which	  increases	  FGF-­‐FGFR	  
affinity	  and	  interacts	  with	  adjoining	  FGFRs	  which	  promotes	  protein-­‐protein	  interactions	  
that	  stabilize	  dimerization.	  15	  Therefore,	  SOS	  can	  promote	  FGF	  signaling	  by	  imitating	  the	  
role	  of	  heparin	  in	  enhancing	  FGF-­‐FGFR	  affinity	  and	  receptor	  dimerization.	  14,15	  
Applications	  and	  Significance	  of	  Heparin:	  
	  Heparin	  is	  found	  in	  mast	  cells	  and	  is	  isolated	  for	  clinical	  uses	  from	  hog	  mucosa	  
or	  beef	  lung.	  It	  is	  released	  from	  mast	  cells	  in	  response	  to	  an	  external	  signal.	  Clinically,	  it	  
is	  commonly	  used	  as	  an	  anticoagulant.	  6	  
A	  major	  characteristic	  of	  heparin	  is	  that	  it	  is	  classified	  as	  a	  linear	  sulfated	  
glycosaminoglycan	  (GAG).	  It	  consists	  predominantly	  of	  a	  repeating	  disaccharide	  
comprised	  of	  an	  uronic	  acid	  residue	  (either	  a	  D-­‐glucuronic	  acid	  or	  L-­‐iduronic	  acid)	  and	  a	  
D-­‐glucosamine,	  which	  is	  either	  N-­‐sulfated	  or	  N-­‐acetylated.	  6	  Alpha	  1,4	  linkages	  connect	  
the	  uronic	  acid	  residue	  and	  D-­‐glucosamine	  in	  the	  structure	  of	  heparin.	  6	  These	  sulfate	  
groups	  impart	  a	  strong	  negative	  charge	  on	  the	  heparin	  chain.	  8	  The	  content	  of	  this	  
compound	  consists	  of	  multiple	  residues	  that	  contain	  sulfur	  groups,	  which	  play	  important	  
roles	  in	  the	  regulation	  of	  heparin	  specificity	  in	  cellular	  proteins	  including	  various	  growth	  
and	  differentiation	  factors,	  extracellular	  matrix	  (ECM)	  components,	  protease	  inhibitors,	  
protease,	  lipoprotein	  lipase,	  and	  various	  pathogens.	  6	  Each	  disaccharide	  unit	  contains	  a	  
sulfur	  group	  at	  the	  2-­‐amino	  position	  on	  the	  uronic	  acid	  residue	  and	  the	  6-­‐amino,	  3-­‐
amino,	  and	  N-­‐amino	  groups	  of	  the	  glucosamine	  residue.	  6,9,10	  The	  interactions	  of	  these	  
sulfur	  groups	  with	  other	  proteins	  play	  a	  pivotal	  role	  in	  various	  patho-­‐physiological	  
phenomena	  through	  electrostatic	  interactions.	  	  
The	  extracellular	  matrix	  plays	  a	  central	  role	  in	  the	  control	  of	  cell	  proliferation,	  
differentiation,	  and	  migration	  by	  mediating	  cell	  adhesions	  and	  communication.	  6,11	  
Therefore,	  the	  extracellular	  matrix	  contains	  heparin	  binding	  proteins	  that	  help	  regulate	  
the	  physiological	  processes	  that	  heparin	  contributes	  to.	  Heparin	  binding	  proteins	  are	  
produced	  by	  diverse	  cell	  types	  and	  are	  found	  in	  a	  variety	  of	  tissues.	  These	  groups	  
include	  the	  proteins	  of	  the	  circulatory	  system	  involved	  in	  coagulation,	  many	  growth	  
factors,	  and	  proteins	  involved	  in	  lipid	  metabolism.	  6,11	  Heparin	  binding	  proteins	  are	  
characterized	  by	  a	  certain	  distribution	  of	  basic	  amino	  acids,	  especially	  lysines	  and	  
arginines	  along	  a	  relatively	  short	  amino	  acid	  sequence.	  6	  There	  are	  many	  proteins	  that	  
contain	  such	  sequences	  which	  illustrates	  the	  versatile	  interactions	  that	  heparin	  has	  with	  
other	  proteins.	  6	  Heparin	  adopts	  a	  helical	  structure	  and	  has	  torsion	  angles	  associated	  
with	  the	  intermonosaccharide	  glycosidic	  bonds	  and	  the	  pyranose	  ring	  of	  α-­‐iduronic	  
acid.12	  The	  pyranose	  ring	  of	  the	  α-iduronic	  acid	  can	  potentially	  adopt	  many	  
conformations.	  The	  conformational	  flexibility	  of	  this	  ring	  enhances	  the	  specificity	  of	  
heparin	  when	  binding	  to	  other	  protein.	  12	  Furthermore,	  the	  ability	  of	  this	  iduronic	  acid	  
to	  adopt	  multiple	  ring	  conformations	  enhances	  the	  formation	  of	  a	  kink,	  which	  is	  formed	  
when	  heparin	  binds	  to	  other	  proteins	  such	  as	  fibroblast	  growth	  factors.	  12,13	  This	  kink	  
provides	  optimal	  ionic	  and	  van	  der	  Waals	  contact	  with	  the	  protein	  that	  heparin	  is	  
binding	  to	  which	  influences	  the	  specificity	  of	  heparin.	  12,13	  The	  overall	  heparin	  helical	  
structure	  is	  maintained	  when	  bound	  to	  another	  molecule,	  but	  local	  conformational	  
changes	  in	  the	  heparin	  structure	  occur	  due	  to	  the	  backbone	  torsion	  angles	  formed	  from	  
the	  kink.	  12	  The	  spatial	  distribution	  of	  basic	  amino	  acids	  in	  the	  heparin-­‐binding	  loops	  
influences	  the	  distribution	  of	  sulfate	  groups	  in	  the	  interacting	  portion	  of	  the	  heparin	  
chain,	  and	  thus	  provide	  the	  best	  ionic	  and	  surface	  interactions	  for	  heparin	  binding.	  12	  
Need	  for	  Purification	  of	  Heparin:	  
In	  2008,	  over-­‐sulfated	  chondroitin	  sulfate	  (OSCS)	  and	  dextran	  sulfate	  (DS),	  two	  
compounds	  similar	  to	  heparin,	  were	  found	  in	  batches	  of	  heparin	  that	  killed	  hundreds	  of	  
patients.2,5	  The	  similarities	  between	  OSCS,	  DS,	  and	  heparin	  made	  it	  impossible	  to	  purify	  
heparin.	  Heparin	  and	  OSCS	  are	  alike	  in	  that	  both	  are	  members	  of	  a	  family	  called	  
glycosaminoglycans	  and	  have	  similar	  molecular	  weights.	  OSCS	  has	  harmful	  effects	  on	  the	  
body	  because	  it	  activates	  the	  kini-­‐kallikrein	  pathway,	  which	  eventually	  creates	  
brandykinin.3,4	  Brandykinin	  leads	  to	  low	  blood	  pressure	  by	  inducing	  a	  physiological	  response	  
that	  dilates	  the	  blood	  vessels.	  Upon	  exposure	  to	  the	  contaminated	  heparin,	  other	  
symptoms	  included	  shortness	  of	  breath,	  nausea,	  rashes,	  and	  tachychardia.	  2,5	  These	  
contaminated	  shipments	  of	  heparin	  came	  from	  the	  Changzho	  SPL	  plant	  in	  China	  and	  
affected	  over	  10	  countries	  and	  an	  extensive	  recall	  was	  required.	  4	  	  	  	  
Fibroblast	  Growth	  Factors	  (FGFs),	  Fibroblast	  Growth	  Factor	  Receptors,	  and	  Heparin:	  
The	  fibroblast	  growth	  factor	  family	  includes	  23	  structurally	  related	  proteins	  with	  
a	  core	  region	  of	  approximately	  130	  residues	  that	  consist	  of	  twelve	  antiparallel	  β-­‐
strands.	  18,19	  In	  development,	  FGF’s	  are	  required	  for	  embryogenesis	  and	  organogenesis,	  
which	  is	  the	  production	  and	  development	  of	  the	  organs.	  14	  FGF’s	  continue	  to	  regulate	  
tissue	  homeostasis	  in	  the	  adult	  and	  play	  important	  roles	  in	  angiogenesis,	  differentiation,	  
tissue	  repair,	  wound	  healing	  and	  cholesterol	  metabolism.14,20	  	  	  
FGF’s	  perform	  their	  diverse	  functions	  by	  binding	  and	  activating	  cell	  surface	  FGF	  
receptors	  (FGFR).	  FGF-­‐FGFR	  binding	  specificity	  is	  essential	  for	  the	  regulation	  of	  FGF	  
signaling	  and	  is	  determined	  by	  differences	  in	  the	  protein’s	  primary	  sequence.	  7,8	  
Receptor	  dimerization	  in	  FGF	  signaling	  requires	  the	  presence	  of	  the	  highly	  sulfated	  
heparin	  polysaccharide	  chains	  and	  can	  cause	  a	  wide	  spectrum	  of	  human	  pathological	  
conditions	  including	  blood	  coagulation	  and	  cancer.	  8	  Signaling	  begins	  with	  the	  formation	  
of	  a	  ternary	  complex	  of	  FGF,	  FGFR,	  and	  heparin.	  7	  Heparin	  is	  known	  to	  bind	  tightly	  to	  
FGFs	  since	  it	  has	  a	  dissociation	  constant	  in	  the	  nanomolar	  range.	  7	  The	  strong	  binding	  of	  
FGFs	  to	  heparin	  is	  important	  physiologically	  because	  it	  deters	  degradation	  of	  FGFs	  from	  
acid	  and	  heat.	  8,	  21	  	  	  
	   There	  are	  four	  known	  FGF	  receptors	  (FGFRs),	  FGFR-­‐1	  through	  FGFR-­‐4.	  8	  The	  
prototypical	  FGFR	  consists	  of	  an	  extracellular	  domain,	  a	  single-­‐pass	  transmembrane	  
helix,	  and	  a	  cytoplasmic	  tyrosine	  kinase	  domain.	  14	  The	  FGFRs	  share	  between	  55%	  and	  
72%	  homology	  at	  the	  protein	  level.	  FGF	  signaling	  is	  triggered	  by	  binding	  of	  the	  ligand	  
(FGF)	  to	  the	  extracellular	  domain	  of	  the	  FGFR,	  which	  causes	  a	  phosphotyrosine-­‐induced	  
conformational	  change	  in	  their	  target	  proteins	  to	  activate	  various	  catalytic	  activities.	  8	  
The	  extracellular	  domain	  consists	  of	  three	  immunoglobulin-­‐like	  domains	  (D1-­‐D3)	  and	  an	  
acid	  box	  (a	  continuous	  stretch	  of	  four	  to	  eight	  acidic	  amino	  acids)	  placed	  between	  the	  
D1	  domain	  and	  the	  D2	  domain.	  14,	  22	  The	  first	  Ig-­‐like	  domain	  is	  thought	  to	  play	  a	  role	  in	  
receptor	  autoinhibition.	  Domains	  II	  and	  II	  constitute	  the	  FGF	  ligand-­‐binding	  site.	  11	  FGF	  
induced	  dimerization	  of	  the	  receptor	  is	  a	  mandatory	  step	  in	  FGF-­‐induced	  signaling.	  
Binding	  of	  FGF	  to	  the	  extracellular	  domain	  of	  the	  FGFR	  leads	  to	  receptor	  dimerization	  
and	  juxtaposition	  of	  the	  tyrosine	  residues	  in	  the	  cytoplasmic	  domain.	  8	  	  [The	  receptors	  
then	  become	  capable	  of	  phosphorylating	  specific	  tyrosine	  residues	  on	  their	  own	  and	  
each	  other’s	  cytoplasmic	  tails.	  8,23	  Phosphorylation	  of	  seven	  tyrosine	  residues	  in	  the	  
receptor	  site	  is	  an	  essential	  step	  in	  activating	  the	  downstream	  signaling	  process	  to	  
induce	  physiological	  processes.	  8	  Such	  signaling	  pathways	  include	  the	  PLCλ,	  Src,	  Crk-­‐
mediated,	  and	  SNT-­‐1/FRS2	  which	  are	  involved	  in	  cytoskeleton	  alteration,	  linking	  FGFR	  
signaling	  to	  a	  protein	  that	  binds	  actin,	  mitogenesis,	  and	  growth	  factor	  induced	  cell-­‐cycle	  
progression	  respectively.	  8,24	  	  
	   As	  mentioned	  before,	  different	  FGFs	  can	  induce	  a	  variety	  of	  responses	  in	  the	  
body	  since	  they	  can	  bind	  to	  a	  range	  of	  target	  cells	  that	  include	  but	  are	  not	  limited	  to	  
fibroblasts,	  endothelial	  cells	  and	  keratinocytes.	  8	  FGFs	  have	  specific	  receptor	  sites	  on	  the	  
surface	  of	  their	  respective	  target	  cells.	  Therefore,	  cells	  must	  express	  different	  forms	  of	  
the	  FGF	  receptor.	  This	  is	  accomplished	  through	  the	  expression	  of	  splice	  variants	  of	  a	  
given	  FGFR	  gene	  or	  by	  expression	  of	  different	  FGFR	  genes	  themselves.	  8	  Alternate	  
splicing	  of	  the	  FGFR	  gene	  codes	  for	  a	  variety	  of	  different	  receptor	  protein	  isoforms	  made	  
possible	  because	  of	  the	  structure	  of	  the	  respective	  genes.	  8	  A	  5’	  non-­‐translated	  
sequence,	  a	  hydrophobic	  signal	  sequence,	  the	  IgI	  and	  IgII	  sequences	  separated	  by	  an	  
acid	  box,	  the	  5’	  end	  of	  the	  IgIII	  sequence	  followed	  by	  three	  possible	  3’	  ends	  of	  IgIII	  that	  
are	  due	  to	  alternative	  splicing,	  the	  transmembrane	  domain,	  and	  finally	  the	  kinase	  
domain	  are	  found	  in	  the	  mRNA	  that	  codes	  for	  the	  FGFR	  prior	  to	  splicing.	  8,25	  Different	  
exon	  usage	  allows	  the	  translation	  of	  proteins	  which	  may	  be	  prematurely	  truncated,	  lack	  
Ig-­‐like	  domains,	  or	  utilize	  different	  coding	  regions	  for	  the	  same	  Ig-­‐like	  domains.	  8	  This	  
results	  in	  different	  expression	  of	  the	  mRNA	  for	  FGFRs	  and	  thus	  altered	  specificity	  for	  
different	  FGFs.	  	  
	   Even	  though	  the	  IgIII	  domains	  (IgIIIa,	  IgIIIb,	  and	  IgIIIc)	  that	  play	  a	  pivotal	  role	  in	  
FGF	  binding	  specificity	  are	  more	  homologous	  between	  genes	  than	  between	  each	  other,	  
there	  are	  other	  receptor	  domains	  besides	  IgIII	  that	  affect	  binding	  specificity.	  8,26	  
Therefore,	  diversity	  in	  FGF	  signaling	  can	  be	  achieved	  through	  analogous	  splice	  variants	  
of	  different	  genes	  as	  well.	  	  	  
FGF	  Signaling	  in	  Diseases:	  
	   Human	  cancers	  develop	  through	  a	  multi-­‐stage	  process	  that	  transforms	  normal	  
cells	  into	  malignant	  cells	  by	  accumulating	  a	  number	  of	  genetic	  changes.	  11	  Because	  FGFs	  
activate	  many	  signal	  transduction	  cascades,	  various	  genetic	  programs	  are	  activated	  
which	  stimulate	  cell	  growth,	  regulate	  transcription	  factors,	  and	  inhibit	  pathways	  of	  cell	  
death.	  27	  Therefore,	  all	  components	  of	  this	  pathway,	  from	  the	  polypeptide	  growth	  
factors	  to	  the	  transcription	  factors	  are	  potential	  oncoproteins.	  27Decreased	  regulation	  at	  
any	  of	  these	  cascades	  controlled	  by	  FGF	  signaling	  promotes	  cell	  growth	  beyond	  control	  
and	  causes	  cancer.	  27,29	  FGFs	  and	  FGFRs	  seem	  to	  stimulate	  several	  steps	  of	  cancer	  
progression	  including	  cancer	  cell	  proliferation	  and	  survival,	  as	  well	  as	  invasion,	  
metastasis,	  and	  angiogenesis.	  8	  There	  are	  no	  documented	  mutations	  in	  FGFs	  themselves	  
so	  the	  most	  logical	  mechanism	  that	  FGFs	  contribute	  to	  unregulated	  cell	  growth	  is	  by	  
overexpression.	  27	  This	  most	  likely	  occurs	  through	  the	  overexpression	  of	  FGFs	  by	  the	  
tumor	  cells	  themselves,	  secretion	  of	  FGFs	  by	  the	  stromal	  cells	  in	  response	  to	  a	  signal	  
from	  the	  tumor	  cells,	  and	  secretion	  of	  FGFs	  by	  the	  tumor	  in	  response	  to	  a	  signal	  from	  
non-­‐transformed	  cells.	  27	  Examples	  of	  these	  mechanisms	  are	  illustrated	  by	  FGF-­‐2	  and	  
FGF-­‐5.	  FGF-­‐2	  has	  shown	  to	  be	  associated	  with	  the	  degree	  of	  malignancy	  and	  vascularity	  
in	  human	  gliomas,	  which	  is	  expected	  since	  FGF-­‐2	  acts	  as	  an	  autocrine	  growth	  factor	  on	  
the	  tumors	  and	  promotes	  angiogenesis	  in	  the	  surrounding	  stroma.	  27	  FGF-­‐5	  is	  secreted	  
as	  a	  paracrine	  growth	  factor	  by	  the	  non-­‐transformed	  cells	  in	  the	  tumor	  stroma	  in	  
response	  to	  signaling	  factors	  present	  in	  the	  tumor.	  Another	  possibility	  for	  deregulation	  
of	  FGF	  signaling	  in	  cancer	  could	  be	  due	  to	  the	  mobilization	  of	  FGFs	  from	  the	  extracellular	  
matrix.	  27	  Two	  models	  for	  the	  release	  of	  FGFs	  include	  enzymatic	  cleavage	  of	  extracellular	  
matrix	  components	  by	  proteases	  or	  heparanases,	  an	  enzyme	  that	  acts	  to	  degrade	  
heparin,	  or	  by	  binding	  to	  carrier	  proteins,	  which	  deliver	  FGFs	  to	  their	  receptors.27	  
Studies	  have	  investigated	  the	  release	  of	  soluble	  FGFs	  from	  the	  ECM	  by	  digestion	  of	  the	  
glycosaminoglycan	  portion	  of	  heparin-­‐like	  glycosaminoglycans	  (HLGAGs)	  through	  the	  
activity	  of	  heparanases.	  	  HLGAGs	  are	  required	  components	  of	  the	  activated	  receptor	  
complex	  along	  with	  FGFs.	  FGF	  binding	  proteins	  present	  FGFs	  at	  the	  cell	  surface	  where	  it	  
interacts	  with	  HLGAGs	  and	  in	  turn	  present	  FGF	  to	  the	  FGFR	  to	  activate	  various	  signal	  
cascades.	  The	  mammalian	  gene	  for	  heparanase	  is	  expressed	  at	  the	  mRNA	  and	  protein	  
levels	  in	  metastic	  human	  and	  rat	  cell	  lines.	  27	  The	  ability	  of	  heparanases	  to	  release	  
bound	  stores	  of	  FGFs	  triggers	  angiogenesis,	  which	  is	  consistent	  with	  the	  observed	  role	  of	  
heparanases	  in	  promoting	  metastasis.	  27	  Therefore,	  regulating	  expression	  of	  
heparanases	  some	  tumors	  may	  be	  able	  to	  mobilize	  FGFs	  from	  the	  ECM.	  	  
	   With	  regards	  to	  pathogen	  infections,	  growth	  factors	  are	  incorporated	  into	  the	  
genome	  of	  infectious	  pathogens	  because	  they	  provide	  an	  advantage	  of	  allowing	  the	  
infectious	  agent	  to	  bind	  to	  the	  host	  cell	  and	  gain	  access	  to	  the	  surface	  proteins	  that	  
facilitate	  infection.	  28	  Furthermore,	  pathogens	  utilize	  GAG-­‐mediated	  processes	  such	  as	  
chemokine	  signaling.	  It	  is	  known	  that	  GAG’s	  play	  a	  role	  in	  the	  herpes	  simplex	  virus	  (HSV)	  
and	  human	  immunodeficiency	  virus	  (HIV)	  based	  on	  the	  inhibitory	  effect	  of	  heparin.	  28,30	  	  	  
Heparin	  binding	  FGFs	  are	  found	  in	  the	  viral	  envelope,	  which	  suggests	  viral	  infection	  is	  
linked	  to	  growth	  factor	  signaling	  by	  mimicking	  the	  heparin-­‐binding	  domain.	  28	  GAG-­‐
binding	  proteins	  are	  important	  in	  adhesion	  and	  invasion	  when	  dealing	  with	  bacterial	  
pathogenesis.	  28	  Diverse	  bacteria	  bind	  to	  heparin	  on	  the	  surface	  of	  cells.	  For	  example,	  
Chlamydia	  attaches	  to	  the	  host	  and	  is	  mediated	  by	  GAG	  bridges	  between	  protein	  
receptors	  on	  both	  bacteria	  and	  host	  cells.	  28,31	  Thus,	  heparin	  controls	  invasion	  of	  
bacteria	  into	  the	  host	  cell.	  28,31	  Therefore,	  heparin	  represents	  a	  new	  antibiotic	  approach	  
because	  it	  facilitates	  bacteria’s	  mechanism	  of	  entering	  into	  the	  host	  cell.	  
	   Bacteria	  are	  protected	  from	  the	  external	  environment	  by	  their	  complex	  outer	  
membrane	  structures.	  The	  membrane	  has	  an	  asymmetric	  lipid	  bilayer	  with	  negatively	  
charged	  lipopolysaccharide	  (LPS)	  molecules	  localized	  on	  the	  outer	  leaflet	  and	  is	  
stabilized	  by	  the	  presence	  of	  cations.	  32	  Many	  studies	  have	  shown	  that	  polycationic	  
molecules	  can	  damage	  the	  outer	  membranes	  of	  bacteria	  and	  enhance	  bacterial	  
susceptibility	  to	  hydrophobic	  substances	  such	  as	  antibiotics	  and	  lysozyme.	  32	  A	  known	  
compound	  that	  utilizes	  this	  mechanism	  is	  Polymyxin.	  Polymyxin	  is	  a	  polycationic	  
decapeptide	  antibiotic	  with	  a	  fatty	  acid	  tail	  that	  contains	  five	  positively	  charged	  groups	  
and	  no	  negatively	  charged	  groups.	  33	  Its	  ultimate	  lethal	  target	  is	  generally	  thought	  to	  be	  
the	  cytoplasmic	  membrane	  to	  which	  it	  will	  become	  bound	  to	  phospholipids	  and	  therefor	  
destroy	  the	  cytoplasmic	  membrane	  of	  the	  bacteria.	  33	  Polymyxin	  gains	  access	  through	  
the	  disruption	  of	  the	  outer	  membrane	  by	  causing	  extensive	  alterations	  due	  the	  
polycationic	  nature	  of	  its	  structure	  by	  binding	  to	  the	  anionic	  core-­‐components	  of	  LPS	  
molecules.	  32,	  33	  Therefore,	  polycationic	  molecules	  have	  proven	  to	  be	  effective	  methods	  
of	  treatment	  for	  bacterial	  infections.	  	  
	   A	  novel	  heparin-­‐binding	  affinity	  tag	  was	  developed	  by	  Dr.	  Kumar	  to	  
exhibit	  a	  greater	  binding	  affinity	  for	  heparin	  and	  thus	  optimize	  purification.	  Applications	  
of	  this	  enhanced	  heparin	  binding	  will	  be	  critical	  to	  this	  project	  since	  it	  is	  known	  that	  
heparin	  plays	  a	  crucial	  role	  in	  bacterial	  infection	  pathways.	  The	  polycationic	  nature	  of	  
the	  HB	  portion	  of	  the	  GST-­‐HB	  peptide	  developed	  by	  Dr.	  Kumar	  is	  due	  to	  the	  presence	  of	  
many	  arginine	  and	  lysine	  amino	  acids.	  Therefore	  it	  is	  expected	  to	  exhibit	  antimicrobial	  
properties	  by	  binding	  to	  heparin	  in	  a	  fashion	  much	  like	  FGF-­‐1.	  The	  following	  amino	  acid	  
sequence	  of	  FGF-­‐1	  highlights	  the	  heparin	  binding	  site	  region	  in	  bold:	  
MAEGEITTFTALTEKFNLPPGNYKKPKLLYSNGGHFLRILPDGTVDGTRDRSDQHIQLQLSAESVGEV
YIKSTETGQYLAMDTDGLLYGSQTPNEECLFLERLEENHYNTYISKKHAEKNWFVGLKKNGSCKRGP
RTHYGQKAILFLPLPVSSD.	  This	  sequence	  of	  amino	  acids	  creates	  a	  positive	  charge	  for	  the	  
heparin-­‐binding	  domain	  of	  FGF-­‐1,	  which	  interacts	  with	  the	  negatively	  charged	  heparin,	  a	  
polysaccharide	  that	  is	  crucial	  for	  the	  activity	  and	  function	  of	  various	  proteins.	  	  	  The	  
polyanionic	  surface	  of	  heparin	  binding	  to	  this	  polycationic	  site	  of	  FGF-­‐1	  is	  critical	  for	  FGF	  
interactions.	  Therefore,	  the	  polycationic	  nature	  of	  the	  HB	  peptide	  is	  expected	  to	  exhibit	  
a	  great	  affinity	  for	  heparin	  and	  thus	  inhibit	  the	  FGF-­‐FGFR	  interactions	  that	  are	  essential	  














Materials	  and	  Methods	  
Materials	  include	  Escheria	  coli	  BL-­‐21	  cell,	  pGEX-­‐KG-­‐Hep	  expression	  vector,	  GST-­‐
HB	  glycerol	  stock,	  isopropyl	  B-­‐D-­‐1-­‐thiogalactopyranoside	  (IPTG),	  terrific	  broth	  (TB),	  
100%	  glycerol,	  ampicillin,	  phosphate	  buffered	  saline	  (PBS),	  L-­‐reduced	  glutathione	  99%,	  
GSH	  Speharose	  resin,	  20%	  ethanol,	  8M	  urea,	  thrombin,	  10KDa	  Macrosep	  Advance	  
Centrifugal	  Device,	  30%	  acrylamide,	  sodium	  dodecyl	  sulfate	  (SDS),	  ammonium	  
persulfate	  (APS),	  TEMED,	  Coomassie	  Blue,	  methanol,	  2-­‐B-­‐mercaptoethanol,	  
bromophenol	  blue,	  hydrochloric	  acid,	  DH5α	  host	  cells,	  egg	  white	  lysozyme,	  Luria-­‐Bertani	  
(LB)	  agar,	  LB	  broth,	  sterile	  Whatman	  paper	  disks,	  high	  definition	  Sony	  camera.	  
Construction	  of	  Novel	  Antimicrobial	  Peptide	  GST-­‐HB:	  	  	  
The	  nucleotide	  sequence	  corresponding	  to	  HB	  amino	  acid	  sequence	  was	  cloned	  
downstream	  of	  GST	  sequence	  in	  order	  to	  be	  further	  expressed	  at	  high	  yields	  in	  bacterial	  
systems.	  The	  recombinant	  peptide	  was	  cleaved	  from	  the	  fusion	  partner,	  GST,	  by	  using	  a	  
thrombin	  cleavage	  site,	  LVPRGS,	  incorporated	  at	  the	  C-­‐terminal	  end	  of	  the	  peptide	  
between	  GST	  and	  HB.	  	  Critical	  to	  the	  construction	  of	  the	  recombinant	  peptide	  was	  a	  
vector	  developed	  by	  Dr.	  Srinivas	  Jayanthi.	  This	  vector	  carries	  the	  operon	  that	  contains	  
the	  necessary	  genetic	  information	  to	  make	  copies	  of	  mRNA	  corresponding	  to	  the	  
nucleotide	  sequence	  of	  the	  peptide.	  Furthermore,	  it	  contains	  genes	  that	  have	  antibiotic	  
resistance,	  which	  is	  essential	  for	  allowing	  GST-­‐HB	  to	  be	  expressed.	  The	  extensive	  details	  
of	  this	  vector	  are	  detailed	  in	  Figure	  1.	  Since	  only	  the	  HB	  peptide	  is	  thought	  to	  have	  
antimicrobial	  properties,	  its	  separation	  from	  GST,	  using	  thrombin,	  is	  crucial	  for	  further	  
antimicrobial	  studies.	  
	  	  
The	  structure	  above	  shows	  a	  basic	  layout	  of	  the	  peptide.	  	  The	  GST	  portion	  is	  
represented	  in	  blue.	  The	  orange	  portion	  represents	  the	  thrombin	  cleavage	  site	  followed	  
by	  HB	  represented	  in	  green.	  
	  
Figure	  1:	  The	  extensive	  work	  done	  by	  Dr.	  Srinivas	  Jayanthi	  resulted	  in	  the	  development	  
of	  pET-­‐28a:	  the	  vector	  necessary	  to	  clone	  the	  recombinant	  peptide.	  
	  
Overexpression	  of	  GST-­‐HB:	  	  	  
GST-­‐HB	  will	  then	  be	  overexpressed	  in	  BL21	  cells	  using	  already	  established	  
experimental	  methods.	  Glycerol	  stocks	  of	  E.	  Coli	  cells	  transformed	  in	  the	  pGEX-­‐KG-­‐Hep	  
vector	  were	  inoculated	  for	  14-­‐16	  hours	  in	  terrific	  broth	  with	  ampicillin	  (1uL/mL	  of	  
terrific	  broth)	  and	  grown	  overnight	  at	  37	  degrees	  Celsius	  and	  250	  rpm.	  After	  growing	  
GST	   HB	  
overnight,	  5%	  inoculum	  and	  ampicillin	  (still	  1uL/mL)	  were	  added	  to	  autoclaved	  terrific	  
broth.	  This	  was	  then	  allowed	  to	  inoculate	  under	  the	  same	  conditions	  for	  1-­‐1.5	  hours	  to	  
allow	  for	  the	  optical	  density	  of	  the	  solution	  to	  reach	  an	  absorbance	  of	  0.6-­‐1.00	  at	  600	  
nm.	  Cultured	  flasks	  were	  then	  induced	  with	  1mM	  (500	  μL)	  of	  isopropyl	  β-­‐D-­‐1-­‐
thiogalactopyranoside	  (IPTG)	  and	  allowed	  to	  incubate	  for	  another	  four	  hours.	  The	  
culture	  was	  then	  centrifuged at 6000	  rpm	  for	  20	  minutes	  to	  form	  bacterial	  pellets.	  The	  
supernatant	  was	  discarded	  and	  the	  pellets	  were	  resuspended	  in	  approximately	  50	  mLs	  
of	  1xPBS	  buffer	  at	  pH	  7.2.	  These	  samples	  were	  subjected	  to	  centrifugation	  again	  at	  6000	  
rpm	  for	  20	  minutes.	  The	  supernatant	  was	  discarded	  and	  the	  pellets	  were	  stored	  at	  -­‐20	  
degrees	  Celsius	  until	  further	  use.	  The	  overexpression	  of	  GST-­‐HB	  was	  analyzed	  using	  15%	  
sodium	  dodecyl	  sulfate	  polyacrylamide	  gel	  electrophorese	  (SDS-­‐PAGE).	  
Purification	  of	  GST-­‐HB:	  	  	  
Affinity	  chromatography	  using	  GSH	  Sepharose	  was	  performed	  to	  purify	  the	  1L	  
GST-­‐HB	  pellets	  created	  using	  the	  overexpression	  methods	  just	  described.	  The	  pellets	  
made	  using	  the	  previously	  described	  overexpression	  method	  were	  resuspended	  in	  30	  
mLs	  of	  1xPBS	  buffer	  at	  pH	  of	  7.2.	  While	  on	  ice,	  sonication	  of	  the	  sample	  was	  employed	  
for	  30	  cycles	  at	  10-­‐second	  intervals	  in	  order	  to	  lyse	  the	  protein.	  After	  sonication,	  the	  
sample	  was	  centrifuged	  at	  19,000	  rpm	  for	  20	  minutes	  and	  the	  supernatant	  was	  carefully	  
loaded	  onto	  the	  GSH	  sepharose	  column	  at	  a	  flow	  rate	  of	  1mL/min	  followed	  by	  washing	  
with	  1xPBS	  at	  pH	  7.2.	  The	  eluent	  buffer,	  10	  mM	  glutathione,	  was	  then	  loaded	  onto	  the	  
column	  at	  a	  flow	  rate	  of	  1mL/min	  to	  elute	  GST-­‐HB	  off	  the	  column.	  Fusion	  protein	  was	  
collected	  at	  this	  step	  and	  then	  subjected	  to	  concentration	  at	  3600	  rpm	  and	  4	  degrees	  
Celsius	  using	  an	  Amicon	  concentrator	  (10Kda	  cutoff)	  until	  a	  final	  volume	  of	  
approximately	  2-­‐3	  mLs	  was	  reached.	  Fractions	  of	  collected	  protein	  eluents	  (supernatant,	  
10mM	  reduced	  glutathione,	  and	  8M	  urea)	  were	  analyzed	  using	  a	  15%	  SDS-­‐PAGE	  gel	  that	  
was	  stained	  with	  Coomassie	  Blue	  to	  determine	  the	  success	  of	  the	  purification.	  The	  pure	  
GST	  peptide	  will	  then	  be	  used	  for	  further	  experiments.	  
Optimal	  Thrombin	  Cleavage	  for	  GST-­‐HB:	  	  
The	  purified	  fusion	  protein	  (GST-­‐HB)	  was	  then	  subjected	  to	  cleavage	  by	  
thrombin.	  The	  concentration	  of	  the	  fusion	  protein	  was	  estimated	  based	  on	  the	  
extinction	  coefficient	  value	  of	  the	  protein	  and	  its	  absorbance	  measured	  using	  UV	  
spectroscopy	  at	  280	  nm.	  One	  Unit	  of	  thrombin	  was	  added	  for	  every	  250	  μg	  of	  fusion	  
protein.	  The	  mixture	  of	  thrombin	  and	  fusion	  protein	  was	  allowed	  to	  incubate	  for	  20	  
hours	  at	  room	  temperature.	  Heat	  treatment	  at	  65°C	  for	  20	  minutes	  yielded	  the	  pure	  HB	  
in	  the	  supernatant.	  After	  that,	  the	  supernatant	  from	  the	  heat	  treatment	  then	  
underwent	  desalting	  using	  80%	  isopropanol.	  After	  isopropanol	  was	  added,	  the	  sample	  
was	  incubated	  at	  -­‐20	  degrees	  Celsius	  for	  3	  hours.	  The	  mixture	  was	  centrifuged	  at	  13,000	  
RPM	  for	  10	  minutes	  and	  the	  supernatant	  was	  removed	  to	  collect	  the	  cleaved	  peptide.	  
The	  resulting	  pellet	  was	  dried	  to	  remove	  any	  trace	  of	  isopropanol.	  	  
Antimicrobial	  Activity:	  	  	  
Antimicrobial	  activity	  of	  GST	  peptide	  was	  measured	  and	  assessed	  on	  a	  gram-­‐
positive	  (BD99)	  and	  gram-­‐negative	  (DH5α)	  bacterial	  strain.	  	  An	  already	  established	  
method	  created	  by	  Vogt	  and	  Bechinger	  was	  used	  to	  quantify	  the	  inhibition	  of	  bacterial	  
growth	  by	  the	  GST	  peptide	  to	  determine	  its	  MIC	  value.	  Experimentation	  using	  different	  
concentrations	  of	  lysozyme,	  fusion	  protein,	  and	  cleaved	  protein	  on	  both	  strains	  of	  
bacteria	  was	  carried	  out	  using	  triplicate	  measures.	  In	  total,	  each	  assay	  consisted	  of	  two	  
plates	  with	  disks	  containing	  the	  samples	  being	  tested	  and	  a	  disk	  containing	  ampicillin.	  
The	  ampicillin	  served	  as	  the	  positive	  control	  for	  the	  experiment.	  A	  third	  plate	  without	  
any	  disks	  plated	  served	  as	  an	  experimental	  control.	  
A	  lysozyme	  assay	  was	  utilized	  for	  standardization.	  A	  stock	  of	  20mM	  lysozyme	  in	  
sterile	  1xPBS	  solution	  was	  created	  and	  underwent	  a	  serial	  dilution	  to	  create	  solutions	  
with	  concentrations	  of	  10mM,	  5mM,	  and	  1mM	  lysozyme	  respectively.	  Each	  strain	  of	  
bacteria	  was	  propagated	  and	  allowed	  to	  grow	  for	  14-­‐16	  hours	  in	  10mLs	  of	  Luria-­‐Bertani	  
broth	  (LB)	  broth.	  Twenty	  mLs	  of	  Luria-­‐Bertani	  (LB)	  agar	  were	  poured	  into	  each	  sterile	  
petri	  plate	  and	  allowed	  to	  solidify.	  Once	  solidified,	  100	  μL	  of	  each	  bacterial	  strain	  was	  
added	  onto	  their	  respective	  plates	  and	  spread	  using	  a	  sterile	  flamed	  instrument.	  Ten	  
microliters	  of	  each	  lysozyme	  concentration	  as	  well	  as	  a	  diluted	  sample	  of	  ampicillin	  (1uL	  
ampicillin	  in	  99uL	  of	  sterile	  1xPBS)	  were	  loaded	  onto	  their	  individual	  sterile	  disk	  and	  
plated	  in	  their	  corresponding	  labeled	  section	  that	  was	  previously	  outlined	  on	  the	  plate.	  
The	  three	  plates	  for	  each	  complete	  assay	  were	  incubated	  at	  37	  degrees	  Celsius	  for	  at	  
least	  15	  hours.	  After	  this	  time	  period,	  the	  plates	  were	  checked	  for	  zones	  of	  inhibition	  on	  
the	  gram	  positive	  and	  gram	  negative	  strains	  of	  bacteria.	  
Solutions	  containing	  1mM,	  0.5mM,	  and	  0.1	  mM	  concentrations	  of	  fusion	  protein	  
and	  cleaved	  peptide	  were	  created	  using	  sterile	  1xPBS	  pH	  7.2.	  These	  were	  tested	  on	  the	  
DH5α	  and	  BD99	  cells	  using	  the	  same	  method	  and	  triplicate	  experimentation	  previously	  
described	  for	  the	  lysozyme	  assay.	  	  
Results	  and	  Discussion	  
Overexpression	  and	  Purification	  of	  GST-­‐HB:	  
	   The	  overexpression	  of	  GST-­‐HB	  was	  achieved	  after	  adding	  500	  μL	  (1mM) of	  IPTG	  
to	  the	  respective	  cultured	  flasks.	  A	  sample	  of	  the	  culture	  was	  taken	  before	  adding	  IPTG	  
and	  after	  adding	  IPTG	  to	  determine	  the	  success	  of	  overexpression.	  A	  strong	  band	  at	  30	  





Figure	  2:	  SDS-­‐PAGE	  of	  GST-­‐HB	  with	  a	  molecular	  weight	  of	  30	  kDa	  indicated	  by	  the	  black	  
arrow.	  Lane	  1	  corresponds	  with	  the	  protein	  marker,	  lane	  2	  is	  the	  uninduced	  sample,	  and	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   The	  purification	  of	  pellets	  created	  in	  overexpression	  was	  accomplished	  by	  using	  
GSH-­‐Sepharose	  column	  chromatography.	  Eluents	  collected	  after	  loading	  the	  
supernatant	  followed	  by	  washing	  with	  1xPBS-­‐pH	  7.2,	  10mM	  glutathione,	  and	  8M	  urea	  
were	  analyzed	  using	  SDS-­‐PAGE	  techniques	  as	  well.	  A	  strong,	  pure	  band	  at	  30	  kDa	  
indicates	  a	  successful	  purification	  of	  GST-­‐HB	  as	  shown	  in	  Figure	  2.	  
	  
	   	  
	  
Figure	  3:	  SDS-­‐PAGE	  of	  GST-­‐HB	  using	  GSH-­‐Sepharose	  column.	  This	  particular	  gel	  indicates	  
two	  replicates	  using	  purification	  methods.	  The	  buffer	  wash	  used	  was	  1xPBS	  at	  a	  pH	  of	  
7.2.	  Lane	  1-­‐	  protein	  marker;	  Lane	  2-­‐pellet;	  Lane	  3-­‐	  8M	  urea	  flow	  through;	  Lane	  4-­‐	  10mM	  
glutathione	  eluent	  (contains	  fusion	  protein);	  Lane	  5-­‐	  supernatant;	  Lane	  6-­‐	  pellet;	  Lane	  7-­‐	  
supernatant;	  Lane	  8-­‐	  10mM	  glutathione	  eluent	  (contains	  fusion	  protein);	  Lane	  9-­‐	  small	  
sample	  from	  lane	  8	  drifted	  over	  into	  lane	  9;	  Lane	  10-­‐	  8M	  urea	  flow	  through.	  
	  
	   Thrombin	  was	  utilized	  to	  cleave	  HB	  from	  GST.	  Cleavage	  of	  GST	  from	  the	  HB	  
portion	  is	  critical	  because	  the	  HB	  portion	  is	  suspected	  to	  have	  antimicrobial	  properties.	  
The	  GST	  portion	  of	  the	  protein	  is	  known	  to	  have	  a	  molecular	  weight	  of	  26,000	  Daltons	  
175	  	  80	  54	  	  45	  	  	  30	  	  25	  	  	  17	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  	  	  	  	  	  	  	  	  	  2	  	  	  	  	  	  	  	  	  3	  	  	  	  	  	  	  	  	  	  4	  	  	  	  	  	  	  5	  	  	  	  	  	  	  	  	  	  6	  	  	  	  	  	  	  	  7	  	  	  	  	  	  	  	  8	  	  	  	  	  	  	  	  	  	  	  9	  	  	  	  	  	  10 
while	  the	  peptide	  has	  a	  molecular	  weight	  of	  4,000	  Daltons.	  Since	  the	  GST	  portion	  of	  the	  
protein	  is	  significantly	  bigger	  than	  the	  HB	  peptide,	  a	  large	  pure	  band	  occurring	  at	  26,000	  
Daltons	  and	  smaller,	  pure	  band	  at	  4,000	  Daltons	  indicates	  a	  successful	  thrombin	  
cleavage.	  After	  heat	  treatment,	  the	  supernatant	  contains	  the	  pure	  HB,	  which	  is	  





Figure	  4:	  SDS-­‐PAGE	  of	  GST-­‐HB	  thrombin	  cleavage.	  	  Lane	  1	  corresponds	  to	  the	  heat	  
supernatant	  collected	  from	  the	  thrombin	  cleavage	  containing	  the	  HB	  peptide.	  Lane	  2	  
indicates	  heat	  supernatant	  containing	  peptide	  as	  well.	  Lane	  1	  and	  lane	  2	  are	  from	  two	  
different	  purification	  samples.	  Lane	  3	  and	  lane	  4	  show	  successful	  cleavage	  of	  GST	  from	  
the	  HB	  peptide	  using	  thrombin.	  Lane	  5	  is	  the	  GST-­‐HB	  peptide	  before	  cleavage	  using	  
thrombin.	  Lane	  6	  is	  the	  protein	  marker.	  The	  red,	  blue,	  and	  orange	  arrows	  correspond	  to	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Gram	  Positive	  and	  Gram	  Negative	  Antimicrobial	  Assays:	  
Initial	  testing	  of	  the	  antimicrobial	  properties	  of	  the	  GST-­‐HB	  peptide	  were	  
accomplished	  by	  testing	  1mM,	  0.5	  mM,	  and	  0.1	  mM	  concentrations	  of	  the	  fusion	  
protein	  on	  both	  a	  gram	  positive	  (BD99)	  and	  gram	  negative	  (DH5α)	  bacterial	  strains.	  
After	  the	  purity	  of	  the	  peptide	  was	  determined	  by	  cleavage	  with	  thrombin,	  taking	  the	  
absorbance	  of	  a	  sample	  dissolved	  in	  sterile	  1xPBS	  and	  applying	  Beer’s	  Law	  determined	  
the	  pure	  peptide	  concentration.	  This	  concentration	  was	  used	  to	  create	  a	  stock	  solution	  
of	  1mM	  peptide,	  which	  then	  underwent	  a	  serial	  dilution	  to	  create	  0.5	  mM,	  0.1	  mM,	  and	  
0.05	  mM	  solutions	  of	  peptide.	  Ten	  microliters	  of	  each	  concentration	  was	  plated	  using	  
sterile	  Whatman	  disks	  and	  tested	  on	  a	  gram-­‐positive	  (BD99)	  and	  gram-­‐negative	  (DH5α)	  
bacterial	  strain.	  Each	  plate	  was	  incubated	  at	  37	  degrees	  Celsius	  for	  at	  least	  12-­‐15	  hours	  
before	  being	  checked	  for	  zones	  of	  inhibition.	  Finding	  a	  zone	  of	  inhibition	  indicates	  that	  
there	  is	  indeed	  antimicrobial	  activity	  and	  therefore	  rendered	  successful	  results.	  
Similar	  experimental	  techniques	  were	  performed	  using	  triplicate	  measurements	  
and	  concentrations	  of	  1mM,	  0.5	  mM,	  0.1	  mM,	  and	  0.05mM	  lysozyme.	  Lysozyme	  is	  
known	  to	  be	  an	  effective	  inhibitor	  of	  the	  growth	  of	  bacterial	  cells	  by	  cleaving	  the	  
peptidoglycan	  found	  in	  both	  gram-­‐positive	  and	  gram-­‐negative	  bacterial	  cell	  walls.	  
Therefore,	  lysozyme	  was	  chosen	  for	  standardization	  of	  the	  peptide	  and	  fusion	  protein	  
assays.	  
Any	  antibacterial	  activity	  documented	  due	  to	  the	  fusion	  protein	  or	  peptide	  
shows	  promising	  applications	  towards	  inhibiting	  growth	  for	  various	  viruses	  and	  cancer	  
cell	  lines.	  
	  	  
Figure	  5:	  Result	  of	  testing	  1mM,	  0.5	  mM,	  and	  0.1	  mM	  concentrations	  of	  the	  GST-­‐HB	  
fusion	  protein	  using	  BD99.	  Clear	  zones	  of	  inhibition	  are	  seen	  for	  ampicillin	  (positive	  
control)	  and	  20mM	  lysozyme.	  No	  clear	  zones	  of	  inhibition	  were	  recorded	  for	  the	  
different	  concentrations	  of	  fusion	  protein.	  
	  
	   	  
	  
	   	  
	  
	  
	  Figure	  6:	  Result	  of	  testing	  1mM,	  0.5	  mM,	  0.1	  mM,	  and	  0.05mM	  concentrations	  of	  pure	  
peptide.	  Zones	  of	  inhibition	  were	  recorded	  for	  all	  concentrations	  of	  the	  peptide	  and	  
ampicillin	  (positive	  control).	  
	  




	  Figure	  7:	  Result	  of	  testing	  1mM,	  0.5	  mM,	  0.1mM,	  and	  0.05	  mM	  lysozyme	  
concentrations.	  Clear	  zones	  of	  inhibition	  were	  recorded	  for	  the	  different	  concentrations	  
of	  lysozyme	  indicating	  positive	  results.	  Ampicillin	  was	  used	  as	  the	  positive	  control.	  
	  
	  




Figure	  9:	  Result	  of	  testing	  1mM,	  0.5	  mM,	  and	  0.1	  mM	  concentrations	  of	  the	  GST-­‐HB	  
fusion	  protein	  on	  DH5α.	  A	  clear	  zone	  of	  inhibition	  is	  seen	  for	  ampicillin	  (positive	  
control).	  Antimicrobial	  activity	  is	  seen	  for	  20mM	  lysozyme	  as	  well	  (indicated	  by	  fuzzy	  
zone	  surrounding	  disk).	  However,	  no	  clear	  zones	  of	  inhibition	  were	  recorded	  for	  the	  
different	  concentrations	  of	  fusion	  protein.	  
	  
	   	  	  
	  
	  Figure	  10:	  Result	  of	  testing	  1mM,	  0.5	  mM,	  0.1	  mM,	  and	  0.05mM	  concentrations	  of	  pure	  
peptide	  on	  DH5α.	  No	  zones	  of	  inhibition	  were	  recorded	  for	  all	  concentrations	  of	  the	  





	  Figure	  11:	  Result	  of	  testing	  1mM,	  0.5	  mM,	  0.1mM,	  and	  0.05	  mM	  lysozyme	  
concentrations	  on	  DH5α	  .	  No	  clear	  zones	  of	  inhibition	  were	  recorded	  for	  the	  different	  
concentrations	  of	  lysozyme.	  Ampicillin	  was	  used	  as	  the	  positive	  control	  again	  and	  had	  a	  
distinct	  zone	  of	  inhibition.	  
	  
Figure	  12:	  For	  each	  triplicate,	  a	  control	  plate	  of	  DH5α	  was	  plated	  to	  show	  a	  clean	  lawn	  
of	  gram-­‐negative	  cells.	  
	  
Conclusions	  
	   Because	  of	  the	  presence	  of	  a	  huge	  affinity	  tag	  like	  GST	  at	  the	  N-­‐terminus	  of	  the	  
HB	  peptide,	  there	  is	  a	  possibility	  for	  the	  interference	  of	  the	  GST	  tag	  on	  the	  activity	  of	  the	  
peptide.	  This	  could	  have	  resulted	  in	  loss	  of	  anti-­‐microbial	  activity.	  it	  makes	  sense	  that	  no	  
zones	  of	  inhibition	  were	  recorded	  for	  the	  gram-­‐positive	  or	  gram-­‐negative	  strains	  of	  
bacteria.	  There	  was	  not	  a	  significant	  amount	  of	  HB	  peptide	  to	  document	  antimicrobial	  
activity	  since	  the	  GST	  portion	  of	  the	  peptide	  is	  six	  and	  half	  times	  more	  massive	  than	  the	  
HB	  portion	  of	  the	  peptide.	  Therefore,	  the	  antimicrobial	  activity	  was	  essentially	  diluted	  
due	  to	  proportions	  of	  GST	  to	  HB,	  which	  is	  the	  most	  likely	  cause	  for	  the	  failed	  
documentation	  of	  zones	  of	  inhibition.	  	  
	   Lysozyme	  is	  a	  known	  inhibitor	  of	  bacterial	  growth	  and	  it	  exhibits	  antimicrobial	  
properties	  based	  on	  its	  ability	  to	  cleave	  peptidoglycan	  in	  bacterial	  cell	  walls.	  Gram-­‐
negative	  bacteria	  have	  smaller	  amounts	  of	  peptidoglycan	  in	  their	  cell	  walls,	  whereas	  
gram-­‐positive	  bacteria	  are	  known	  to	  contain	  higher	  concentrations.	  Therefore,	  it	  was	  
expected	  that	  lysozyme	  would	  have	  a	  lesser	  effect	  on	  the	  growth	  of	  gram-­‐negative	  
bacteria.	  	  
Comparing	  the	  lysozyme	  triplicate	  assay	  to	  that	  of	  the	  pure	  peptide	  tested	  on	  
BD99	  revealed	  that	  the	  zones	  of	  inhibition	  achieved	  for	  the	  0.1	  and	  0.05	  mM	  
concentrations	  are	  smaller	  than	  that	  of	  the	  pure	  peptide.	  This	  indicates	  that	  the	  pure	  
peptide	  is	  a	  more	  effective	  inhibitor	  of	  bacterial	  growth	  at	  these	  respective	  
concentrations.	  The	  0.5	  mM	  concentration	  is	  equivalent	  to	  that	  of	  the	  pure	  peptide	  as	  
well,	  but	  the	  1	  mM	  lysozyme	  zone	  of	  inhibition	  exceeds	  that	  of	  the	  pure	  peptide.	  
Despite	  the	  disparity	  at	  the	  1	  mM	  level,	  the	  pure	  peptide	  has	  established	  that,	  it	  inhibits	  
gram-­‐positive	  bacterial	  growth	  at	  smaller	  concentrations.	  The	  testing	  of	  the	  pure	  HB	  
peptide	  yielded	  small	  zones	  of	  inhibition	  for	  all	  the	  concentrations	  resulting	  in	  successful	  
experimentation	  with	  pure	  peptide	  on	  the	  gram-­‐positive	  strain	  of	  bacteria.	  However,	  
the	  zones	  of	  inhibition	  appeared	  to	  be	  larger	  for	  the	  smaller	  concentrations	  of	  pure	  
peptide,	  which	  was	  contrary	  to	  the	  expected	  results.	  	  
Since	  the	  antimicrobial	  affects	  of	  the	  HB	  portion	  of	  the	  peptide	  depend	  on	  the	  
ability	  of	  the	  peptide	  to	  disperse	  into	  the	  surround	  bacterial	  lawn,	  it	  makes	  sense	  that	  
the	  smaller	  concentration	  of	  the	  peptide	  would	  exhibit	  better	  zones	  of	  inhibition	  since	  
the	  lower	  concentration	  of	  peptide	  could	  exhibit	  a	  greater	  mobility	  factor.	  From	  the	  
consistent	  results	  achieved	  from	  the	  triplicate	  assays,	  it	  can	  be	  inferred	  that	  the	  peptide	  
could	  reach	  maximum	  antimicrobial	  activity	  at	  a	  certain	  concentration.	  However,	  the	  
positive	  results	  of	  this	  assay	  indicate	  a	  degree	  of	  effectiveness	  with	  regards	  to	  this	  gram-­‐
positive	  bacterial	  strain.	  	  
The	  lysozyme	  assay,	  pure	  peptide,	  and	  fusion	  protein	  triplicate	  assays	  did	  not	  
exhibit	  zones	  of	  inhibition	  when	  tested	  on	  E.coli	  DH5α.	  Since	  the	  20	  mM	  concentration	  
of	  lysozyme	  exhibited	  minimal	  amounts	  of	  antimicrobial	  activity,	  further	  
experimentation	  with	  higher	  concentrations	  of	  pure	  peptide	  and	  fusion	  protein	  could	  
expect	  low	  activity	  up	  until	  this	  concentration	  as	  well.	  Since	  the	  amount	  of	  fusion	  
protein	  collected	  from	  each	  purification	  is	  relatively	  small,	  the	  further	  testing	  using	  
concentrations	  at	  or	  above	  20	  mM	  would	  take	  significant	  amounts	  of	  materials,	  time,	  
and	  effort	  beyond	  the	  scope	  of	  this	  project.	  However,	  the	  positive	  results	  obtained	  from	  
testing	  the	  peptide	  on	  gram-­‐positive	  strains	  of	  bacteria	  indicate	  further	  applications	  and	  
















	   Thanks	  to	  the	  funding	  provided	  to	  me	  by	  the	  University	  of	  Arkansas	  Honors	  
College	  through	  the	  Honors	  College	  Research	  Grant,	  I	  was	  able	  to	  successfully	  complete	  
the	  work	  done	  for	  this	  project.	  Without	  the	  financial	  support	  of	  the	  Honors	  College	  
Research	  Grant,	  the	  knowledge	  gained	  from	  the	  results	  of	  this	  project	  would	  not	  have	  
occurred.	  	  Furthermore,	  I	  also	  want	  to	  extend	  a	  huge	  thanks	  to	  Dr.	  Suresh	  Kumar,	  Dr.	  
Srinivas	  Jayanthi,	  and	  Jacqueline	  Morris	  for	  their	  hard	  work,	  enduring	  support,	  and	  















1.	  Chung,	  C.S.;	  Hsiao,	  J.C.,	  Chang,	  Y.S.;	  Chang,	  W.	  “Cell	  surface	  proteoglycans	  are	  
necessary	  for	  A27L	  protein	  mediated	  cell	  fusion:	  identification	  of	  the	  N-­‐terminal	  region	  
of	  A27L	  protein	  as	  the	  glycosaminoglycan-­‐binding	  domain.”	  J.	  Virol.	  1998,	  72,	  1577-­‐
1585.	  
	  
2.	  Kishimoto	  TK,	  Viswanathan	  K,	  Ganguly	  T,	  etc.	  “Contaminated	  Heparin	  Associated	  with	  
Adverse	  Clinical	  Events	  and	  Activation	  of	  the	  Contact	  System.”	  (2008)	  N	  Engl	  J	  Med	  
358(23):	  2457-­‐67.	  
	  
3.	  Liu	  H,	  Zhang	  Z,	  Linhardt	  R.	  “Lessons	  learned	  from	  the	  contamination	  of	  heparin.”	  
(2009)	  Nat.	  Prod.	  Rep.	  26:	  313-­‐321.	  
	  
4.	  Beni	  S,	  Limtiaco	  J,	  Larive	  C.	  “Analysis	  and	  characterization	  of	  heparin	  impurities.”	  
(2011)	  Anal	  Bioanal	  Chem	  399:	  527-­‐539.	  
	  
5.	  Blossom	  D,	  Kallen	  A,	  Patel	  P,	  etc.	  “Outbreak	  of	  Adverse	  reactions	  Associated	  with	  
Contaminated	  Heparin.”	  (2008)	  )	  N	  Engl	  J	  Med	  359.25:	  2674-­‐2684.	  
	  
6.	  Conrad	  HE.	  Heparin-­‐Binding	  Proteins.	  Academic	  Press:	  Boston,	  1998.	  
	  
7.	  Zhang	  F,	  Zhang	  Z,	  Lin	  X,	  Beenken	  A,	  et	  al.	  “Compositional	  Analysis	  of	  Heparin/Heparan	  
Sulfate	  Interacting	  with	  Fibroblast	  Growth	  Factor-­‐Fibroblast	  Growth	  Factor	  Receptor	  
Complexes.”	  (2009).	  Biochemistry	  48:	  8379-­‐8386.	  
	  
8.	  Powers	  C.J.,	  McLeskey	  S.W.,	  Wellstein	  A.	  “Fibroblast	  Growth	  Factors,	  Their	  Receptors	  
and	  Signaling.”	  (2000).	  Endocrine-­‐Related	  Cancer	  7:	  165-­‐197.	  
	  
9.	  Lindhardt,	  R.J.,	  and	  Loganathan,	  D.	  (1990)	  Heparin,	  heparinoids	  and	  heparin	  
oligosaccharides;	  Structure	  and	  biological	  activities.	  In	  Biomimetic	  Polymers	  (Gebelein,	  
G.,	  Ed.)	  pp	  135-­‐173,	  Plenum	  Press,	  New	  York.	  
	  
10.	  Bernfield,	  M.,	  Gotte,	  M.,	  Park,	  P.W.,	  Reizes,	  et	  al.	  (1999)	  Functions	  of	  cell	  surface	  
heparan	  sulfate	  proteoglycans.	  Annu.	  Rev.	  Biochem.	  68,	  729-­‐777.	  
	  
11.	  Jackson	  R.,	  Busch	  S.,	  Cardin	  A.	  “Glycosaminoglycans:	  Molecular	  Properties,	  Protein	  
Interactions,	  and	  Role	  in	  Physiological	  Processes.”	  (1991).	  Physiological	  Review	  71(2):	  
481-­‐539.	  
	  
12.	  Raman	  R.,	  Venkataraman	  G.,	  Ernst	  S.,	  et	  al.	  “Structural	  Specificity	  of	  Heparin	  Binding	  
in	  the	  Fibroblast	  Growth	  Factor	  Family	  of	  Proteins.”	  (2003).	  Proc	  Natl	  Acad	  Sci	  U.S.A,	  
100(5):	  2357-­‐2362.	  
	  
13.	  Venkataraman	  G,	  Sasisekharan	  V,	  Cooney	  C	  L,	  Langer	  R,	  Sasisekharan	  R.	  et	  al.	  “A	  
sterochemical	  approach	  to	  pyranose	  ring	  flexibility:	  its	  implications	  for	  the	  conformation	  
of	  dermatan	  sulfate.:	  (1994).	  Proc	  Natl	  Acad	  Sci	  U.S.A,	  91(13):	  6171-­‐6175.	  
	  
14.	  Hung,	  K.	  Thallapuranam	  S.K.,	  Kumar	  S.,	  Karappana	  K.M.,	  et	  al.	  “Solution	  Structure	  of	  
the	  Ligand	  Binding	  Domain	  of	  the	  Fibroblast	  Growth	  Factor	  Receptor:	  Role	  of	  Heparin	  in	  
the	  Activation	  of	  the	  Receptor.”	  (2005).	  Biochemistry	  44:	  15787-­‐15798.	  
	  
15.	  Plotnikov,	  A.N.,	  Schlessinger	  J.,	  Hubbard	  S.R.,	  Mohammadi,	  M.	  (1999)	  Structural	  
Basis	  for	  FGF	  Receptor	  Dimerization	  and	  Activation.”	  Cell,	  98:	  641-­‐650.	  
	  
16.	  Yeh,	  B.	  Eliseenkova,	  A.V.,	  Plotnikov	  A.N.,	  Green,	  D,	  et	  al.	  “Structural	  Basis	  for	  
Activation	  of	  Fibroblast	  Growth	  Factor	  Signaling	  by	  Sucrose	  Octasulfate.”	  (2002).	  Mol.	  
Cell.	  Biol.	  22:	  7184-­‐7192.	  
	  
17.	  Pellegrini	  L.	  “Role	  of	  Heparin	  Sulfate	  in	  Fibroblast	  Growth	  Factor	  Signaling:	  A	  
Structural	  View.”	  (2001)	  Curr.	  Opin.	  Struct.	  Biol.	  11:	  629-­‐634.	  
	  
18.	  Wesche,	  J.;	  Haglund,	  K.;	  Haugsten,	  E.M.	  Biochem.	  J.	  2011,	  437,	  199-­‐213	  
	  
19.	  Zakrzewska	  M.	  Krowarsch	  D.,	  Wiedlocha	  A.,	  Olsnes	  S.,	  et	  al.	  “Structural	  Requirements	  of	  
FGF-­‐1	  for	  Receptor	  Binding	  and	  Translocation	  into	  Cells.”	  (2006).	  Biochemistry	  45:	  15338-­‐
15348.	  
	  
20.	  Schlessinger,	  J.	  “Common	  and	  distinct	  elements	  in	  cellular	  signaling	  via	  EGF	  and	  FGF	  
receptors.”	  (2004).	  Science	  306:	  1506-­‐1507.	  
	  
21.	  Gospodarowicz	  D,	  Cheng	  J.	  “Heparin	  Protects	  Basic	  and	  Acid	  FGF	  from	  Inactivation.”	  
(1986).	  Journal	  of	  Cell.	  Phys.	  128:	  475-­‐484.	  
	  
22.	  Hung,	  K.W.,	  Kumar	  T.K.S.,	  Chi	  Y.H.,	  Chiu	  I.M.,	  et	  al.	  “Molecular	  Cloning,	  Overexpression,	  
and	  Characterization	  of	  the	  Ligand-­‐Binding	  D2	  Domain	  of	  Fibroblast	  Growth	  Factor	  
Receptor.”	  Biochem.	  Biophys.	  Res.	  Commun.	  317:	  253-­‐258.	  
	  
23.	  Lemmon	  M.A.,	  Schlessinger	  J.	  “Regulation	  of	  Signal	  Transduction	  and	  Signal	  Diversity	  by	  
Receptor	  Oligomerization.”	  Trends	  in	  Biochemical	  Science	  19:	  459-­‐463.	  
	  
24.	  Mohammadi	  M,	  Honegger	  A.M.,	  Rotin	  D.,	  Fischer	  R.,	  et	  al.	  “A	  Tyrosine-­‐
Phosphorylated	  Carboxy-­‐Terminal	  Peptide	  of	  the	  Fibroblast	  Growth	  Factor	  Receptor	  
(Flg)	  is	  a	  Binding	  Site	  for	  the	  SH2	  Domain	  of	  Phospholipase	  C-­‐λ1.”	  (1991).	  Molecular	  and	  
Cellular	  Biology	  11:	  5068-­‐5078.	  
	  
25.	  Johnson	  D.E.,	  Lu	  J.,	  Chen	  H.,	  Werner	  S.,	  et	  al.	  “The	  Human	  Fibroblast	  Growth	  Factor	  
Receptor	  Genes:	  a	  Common	  Structural	  Arrangement	  Underlies	  the	  Mechanisms	  for	  
Generating	  Receptor	  Forms	  that	  Differ	  in	  their	  Third	  Immunoglobulin	  Doman.”	  (1991).	  
Molecular	  and	  Cell.	  Biol.	  11:	  4627-­‐4634.	  
	  
26.	  Ornitz	  D.M.,	  Xu	  J.,	  Colvin	  J.S.,	  McEwen	  D.G.,	  MacArthur	  C.A.,	  et	  al.	  “Receptor	  
Specificity	  of	  the	  Fibroblast	  Growth	  Factor	  Family.”	  (1996).	  Journal	  of	  Biol.	  Chem.	  271:	  
15292-­‐15297.	  
	  
27.	  Wesche,	  J.	  Haglund	  K.,	  Haugsten,	  E.M.	  “Fibroblast	  Growth	  Factors	  and	  Their	  
Receptors	  in	  Cancer.”	  (2011).	  Biochem.	  J.	  437:	  199-­‐213.	  
	  
28.	  Linhardt	  R.,	  Toida	  T.	  “Role	  of	  Glycosaminoglycans	  in	  Cellular	  Communication.”	  
(2004).	  Acc.	  Chem.	  Res.	  37:	  431-­‐438.	  
	  
29.	  Myoken	  Y.,	  Okamoto	  T.,	  Mikio	  J.K.,	  Denry	  S.,	  et	  al.	  “Release	  of	  Fibroblast	  Growth	  
Factor-­‐1	  by	  Human	  Squamous	  Cell	  Carcinoma	  Correlates	  with	  Autocrine	  Cell	  Growth.”	  
(1994).	  In	  Vitro	  Cell	  &	  Develop.	  Bio.	  30:	  790-­‐795.	  
	  
30.	  Frick,	  I.	  M.;	  Schmidtchen,	  A.;	  Sjobring,	  U.	  Interactions	  Between	  M	  Proteins	  of	  
Streptococcus	  pyogenes	  and	  Glycosaminoglycans	  Promote	  Bacterial	  Adhesion	  to	  Host	  
Cells.	  Eur.	  J.	  Biochem.	  2003,	  270,	  2303-­‐2311.	  
	  
31.	  Sawitzky,	  D.	  Protein-­‐Glycosaminoglycan	  Interactions:	  Infectio-­‐logical	  Aspects.	  Med.	  
Microbiol.	  Immunol.	  1996,	  184,	  155-­‐161.	  
	  
32.	  Ellison,	  RT	  D.,	  Theodore	  J.	  Giehl,	  and	  F.	  MARC	  LaForce.	  "Damage	  of	  the	  outer	  
membrane	  of	  enteric	  gram-­‐negative	  bacteria	  by	  lactoferrin	  and	  transferrin."	  Infection	  
and	  Immunity	  56.11	  (1988):	  2774-­‐2781.	  
	  
33.	  Nikaido	  H,	  Vaara	  M.	  Molecular	  basis	  of	  bacterial	  outer	  membrane	  permeability.	  
Microbiological	  Reviews.	  1985;49(1):1-­‐32.	  
	  
	  
	  
	  
	  
	  	  
